Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 18, 2026

2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of

View original at finance.yahoo.com
“The company currently carries a market capitalization of about $14.1 billion.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Joby plans to produce four aircraft a month by 2027 at Ohio facility

    80% confidence
  • Urban air mobility has long lived somewhere between science fiction and city planning decks

    80% confidence
  • For Archer fiscal 2026, losses expected to reduce 7.8% annually to -$0.95 per share

    80% confidence
  • For Joby, current quarter loss per share expected to widen 5.3% YOY to -$0.20

    80% confidence
  • For Archer current quarter, losses expected to decrease 52.8% YOY to -$0.25 per share

    80% confidence
  • Management expects to generate cash, cash equivalents, and short-term investments at the upper end of $500 million to $540 million range for 2025

    80% confidence
  • Wall Street analysts recommend caution with consensus Hold rating for Joby Aviation

    80% confidence
  • For Joby fiscal 2026, loss projected to narrow 11.8% to -$0.75 per share

    80% confidence
  • For Joby, full fiscal year losses seen growing 7.6% annually to -$0.85 per share

    80% confidence
  • Archer Aviation has consensus Moderate Buy rating overall

    80% confidence
  • For Archer current year, losses projected to decline 27.5% YOY to -$1.03 per share

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
2 Top Flying Car Stocks That Cathie Wood Can’t Get Enough Of — Source | Via News | Via News